Oral lactoferrin reduces systemic inflammation, enhances anti-viral responses and modulates immune cell profiles.
Oral lactoferrin reduces systemic inflammation, enhances anti-viral responses and modulates immune cell profiles: a randomised controlled trial in healthy, older adults.
AI Summary
Key Findings
Abstract
This randomised controlled trial examined the effect of a 4-week, high-dose (Lf-High, 600 mg/d) or low-dose (Lf-Low, 200 mg/d) oral lactoferrin (Lf) intervention. placebo on immune cell responses to respiratory virus, immune cell subsets and systemic inflammation. In healthy older adults (103,≥50 years old),cytokine release of interferon (IFN)-α2, IFN-γ, IL-6 and TNF-αfrom rhinovirus A-16 (RV-16) or influenza A virus (H1N1) stimulated peripheral blood mononuclear cells, circulating immune cell subsets, and plasma IL-6, C-reactive protein (CRP) and TNF-αwere assessed. Ninety-seven participants completed the 4-week intervention (Lf-High32, Lf-Low31, placebo34, withdrawals6). There was no difference in RV-16 or H1N1-induced IFN-γrelease between groups. RV-16-induced IL-6 was lower in Lf-High. placebo (= 0·001), and RV-16-induced IFN-α2 was higher in Lf-High. Lf-Low (= 0·04). Lf-High increased total T cells (= 0·03) and CD4T cells (= 0·03). placebo. Lf-Low reduced neutrophil (= 0·04), natural killer cell (= 0·045), activated CD8T cell (= 0·03) andγδT cell (= 0·03) frequency. placebo. Plasma IL-6 (= 0·004) and CRP (= 0·03) were lower following Lf-High. Lf-Low, but not placebo. Both high- and low-dose Lf alteredimmune cell responses after 4 weeks. High-dose increased T-cell subsets, promoting adaptive immunity, and reduced systemic inflammation, while low-dose reduced proinflammatory and cytotoxic immune cells. High- and low-dose Lf supplements may have immunoceutical benefits in older adults.
Affiliation
Bronwyn S Berthon
External References
- PubMed ID:
- 41634901
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.